Reducing affinity as a strategy to stimulate immunomodulatory antibody agonism

Muramatsu, M. et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102553-563 (2000).

CAS Google Scholar

Viant, C. et al. Antibody affinity shapes the choice between the fate of memory B cells and the germinal center. Cell 1831298–1311.e11 (2020).

CAS Google Scholar

Forthal, DN Antibody functions. Microbiol. Spectrum. 21–17 (2014).

Google Scholar

Singh, S. et al. Monoclonal antibodies: a review. Fluent. Clin. Pharmacol. 1385–99 (2018).

Google Scholar

Mullard, A. FDA approves 100th monoclonal antibody product. Nat. Rev. Drug Discov. 20491–495 (2021).

CAS Google Scholar

Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting an antibody of predefined specificity. Nature 256495–497 (1975).

CAS Google Scholar

Clackson, T., Hoogenboom, HR, Griffiths, AD & Winter, G. Manufacture of antibody fragments using phage display libraries. Nature 352624–628 (1991).

CAS Google Scholar

Pedrioli, A. & Oxenius, A. Single B cell technologies for monoclonal antibody discovery. Immunol Trends. 421143-1158 (2021).

CAS Google Scholar

Mayes, PA, Hance, KW & Hoos, A. The promise and challenges of immune agonist antibody development in cancer. Nat. Rev. Drug Discov. 17509–527 (2018).

CAS Google Scholar

White, AL et al. The interaction with FcγRIIB is critical for the agonist activity of the anti-CD40 monoclonal antibody. J. Immunol. 1871754-1763 (2011).

CAS Google Scholar

Yu, X et al. The complex interplay between epitope specificity and isotype dictates the biological activity of human anti-CD40 antibodies. cancer cell 33664–675.e4 (2018).

CAS Google Scholar

White, AL et al. The hinge conformation of human immunoglobulin G2 confers superagonist properties to immunostimulatory cancer antibodies. cancer cell 27138-148 (2015).

CAS Google Scholar

Ahonen, C. et al. The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Nat. Immunol. 3451–456 (2002).

CAS Google Scholar

Dahan, R. et al. The therapeutic activity of agonist anti-CD40 human monoclonal antibodies requires selective engagement of the FcγR. cancer cell 29820–831 (2016).

CAS Google Scholar

Yu, X et al. Isotype switching converts anti-CD40 antagonism to agonism to trigger potent antitumor activity. cancer cell 37850–866.e7 (2020).

CAS Google Scholar

Ma, DY & Clark, EA The role of CD40 and CD154/CD40L in dendritic cells. Semin. Immunol. 21265–272 (2009).

CAS Google Scholar

Yu, X et al. TNF receptor agonists induce distinct receptor groups to mediate differential agonist activity. Common. Biol. 4772 (2021).

CAS Google Scholar

Chester, C., Sanmamed, MF, Wang, J. & Melero, I. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results and future strategies. Blood 13149–57 (2018).

CAS Google Scholar

Chin, SM et al. Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab. Nat. Common. 94679 (2018).

Google Scholar

Gong, J., Chehrazi-Raffle, A., Reddi, S., and Salgia, R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations . J. Immunother. Cancer 68 (2018).

Google Scholar

Paluch, C., Santos, AM, Anzilotti, C., Cornall, RJ & Davis, SJ Immune checkpoints as therapeutic targets in autoimmunity. Front. Immunol. 92306 (2018).

Google Scholar

Curnock, AP et al. Cell-targeted PD-1 agonists that mimic PD-L1 are potent T-cell inhibitors. JCI Overview 6e152468 (2021).

Google Scholar

Bryan, CM et al. Computational design of a synthetic PD-1 agonist. proc. Natl Acad. Know United States 118e2102164118 (2021).

CAS Google Scholar

Lee, JY et al. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat. Common. 713354 (2016).

CAS Google Scholar

Bardhan, K. et al. PD-1-Y248 phosphorylation is a marker of PD-1-mediated inhibitory function in human T cells. Science. representing 917252 (2019).

Google Scholar

Chemnitz, JM, Parry, RV, Nichols, KE, June, CH & Riley, JL SHP-1 and SHP-2 associate with the immunoreceptor tyrosine-based switch pattern of programmed death 1 upon primary lymphocyte stimulation human T cells, but only receptor ligation prevents T cell activation. J. Immunol. 173945–954 (2004).

CAS Google Scholar

Patsoukis, N., Wang, Q., Strauss, L. & Boussiotis, VA Revisiting the PD-1 pathway. Science. Adv. 6eabd2712 (2020).

CAS Google Scholar

Jones, B., Tite, JP, and Janeway, CA Jr. Different phenotypic variants of A20/2J mouse B-cell tumor are selected for by antigen and mitogen-triggered cytotoxicity of L3T4-positive and restricted T-cell clones to AI. J. Immunol. 136348-356 (1986).

CAS Google Scholar

Lu, RM et al. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Science. 271 (2020).

CAS Google Scholar

Tabasinezhad, M. et al. Trends in affinity maturation of therapeutic antibodies: from in vitro sequencing approaches to next-generation approaches. Immunol. Lett. 212106-113 (2019).

CAS Google Scholar

Chodorge, M. et al. A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency. Cell death differs. 191187-1195 (2012).

CAS Google Scholar

Segal, NH et al. Phase I study of utomilumab monotherapy (PF-05082566), a 4-1BB/CD137 agonist, in patients with advanced cancer. Clin. Cancer Res. 241816–1823 (2018).

CAS Google Scholar

Rudnick, SI et al. Influence of antigen affinity and internalization on uptake and penetration of anti-HER2 antibodies in solid tumors. Cancer Res. 712250-2259 (2011).

CAS Google Scholar

Wajant, H. Principles of antibody-mediated TNF receptor activation. Cell death differs. 221727-1741 (2015).

CAS Google Scholar

Roghanian, A. et al. Human FcγRIIB (CD32B) antagonist antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. cancer cell 27473–488 (2015).

CAS Google Scholar

Krissinel, E. Stock-based detection of oligomeric states of proteins in jsPISA. Nucleic Acids Res. 43W314–W319 (2015).

CAS Google Scholar

Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from the crystalline state. J.Mol. Biol. 372774–797 (2007).

CAS Google Scholar

Davis, CB et al. Combination of a PD-1 antagonist and a 4-1BB agonist for the treatment of cancer. International patent publication number WO 2015/119923 A1 (2015).

Korman, AJ et al. Human monoclonal antibodies against programmed death 1 (PD-1) and methods of treating cancer using anti-PD01 antibodies alone or in combination with other immunotherapeutics. International patent publication number WO 2006/121168 A1 (2006).

Keller, T et al. Antibodies which bind to human CD27 and their uses. US Patent 9,169,325 (2015).

Hanke, T et al. Nucleic acids encoding anti-CD28 superagonist antibodies. US Patent 7,585,960 (2009).

Arakawa, F. et al. Cloning and sequencing of the V_H and V_K anti-CD3 monoclonal antibody genes, and construction of a mouse/human chimeric antibody. J. Biochem. 120657–662 (1996).

CAS Google Scholar

Meyer, L. et al. A simplified workflow for monoclonal antibody sequencing. PLOS ONE 14e0218717 (2019).

CAS Google Scholar

Sallusto, F. & Lanzavecchia, A. Efficient soluble antigen presentation by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 1791109–1118 (1994).

CAS Google Scholar

Gate, D. et al. Clonal-expanding CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease. Nature 577399–404 (2020).

CAS Google Scholar

Fernandes, RA et al. Inhibition of immune receptors by forced recruitment of phosphatase. Nature 586779–784 (2020).

CAS Google Scholar

Austin, CD et al. Endocytosis and sorting of ErbB2 and the site of action of anticancer drugs trastuzumab and geldanamycin. Mol. Biol. Cell 155268–5282 (2004).

CAS Google Scholar

Sopp, JM et al. On-target IgG hexamerization driven by a C-terminal IgM tail piece fusion variant confers enhanced complement activation. Common. Biol. 41031 (2021).

CAS Google Scholar